These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 29313286

  • 1. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
    Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.
    Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
    [Abstract] [Full Text] [Related]

  • 2. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
    Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA.
    COPD; 2018 Jan; 15(4):334-340. PubMed ID: 30265816
    [Abstract] [Full Text] [Related]

  • 3. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG.
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [Abstract] [Full Text] [Related]

  • 4. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 5. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA, Birk R, Brealey N, Zhu CQ.
    Adv Ther; 2020 Dec 25; 37(12):4894-4909. PubMed ID: 33011864
    [Abstract] [Full Text] [Related]

  • 6. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
    Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC, Lipson DA.
    Adv Ther; 2020 Sep 25; 37(9):3775-3790. PubMed ID: 32647911
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 25; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 25; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 9. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
    Panettieri RA, Camargo CA, Cheema T, El Bayadi SG, Fiel S, Vila TM, Jain RG, Midwinter D, Thomashow B, Ludwig-Sengpiel A, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2022 Sep 25; 17():2043-2052. PubMed ID: 36072608
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan 25; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 11. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 25; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

  • 12. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Mar 25; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 13. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun 25; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 14. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
    Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.
    Am J Respir Crit Care Med; 2017 Aug 15; 196(4):438-446. PubMed ID: 28375647
    [Abstract] [Full Text] [Related]

  • 15. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2016 Aug 15; 11():971-9. PubMed ID: 27274218
    [Abstract] [Full Text] [Related]

  • 16. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
    Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A.
    Chest; 2014 May 15; 145(5):981-991. PubMed ID: 24385182
    [Abstract] [Full Text] [Related]

  • 17. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

  • 18. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Feb 15; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 20. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul 15; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.